Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 8/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24693005 | 0.90 | MPO (0.42) | GPR84MPOSLC6A4HTR1DHTR1B | |
| SCHEMBL2535339 | 0.84 | MPO (0.56) | GPR84MPOSLC6A4HTR1DHTR1B | |
| SCHEMBL29206367 | 0.83 | HTR2A (0.57) | GPR84MPOSLC6A4ARHTR1D | |
| Hydrochloric Acid SCHEMBL21546063 | 0.83 | MPO (0.54) | GPR84MPOSLC6A4HTR1DHTR1B | |
| SCHEMBL29206370 | 0.82 | HTR2A (0.57) | MPOHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL29206408 | 0.80 | HTR2A (0.38) | GPR84MPOSLC6A4HTR1DHTR1B | |
| SCHEMBL25883633 | 0.77 | HTR2A (0.42) | GPR84MPOSLC6A4ARHTR1D | |
| SCHEMBL24693012 | 0.77 | HTR2A (0.40) | GPR84MPOARHTR1DHTR1B | |
| SCHEMBL29206444 | 0.77 | HTR2A (0.40) | GPR84MPOARHTR1DHTR1B | |
| SCHEMBL13715348 | 0.75 | GPR84 (0.67) | GPR84MPOHTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | Arbormentis LLC (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | HTR2A, GRIN2A, HTR1A | GPR84 131/4885MPO 2251/4885SLC6A4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.